Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week | ALNY Message Board Posts

Alnylam Pharmaceuticals

  ALNY website

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34688 of 34721  at  9/12/2019 1:55:03 PM  by

evernewbliss


 In response to msg 34685 by  Steve_382
view thread

Re: Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week

Near term it will not be good for Alnylam if most patients switch to Vutrisiran. Alnylam doesn’t have to share its revenue on Onpattro with Genzyme but it has to give, I believe, up to 30% of its revenue on Vutrisiran to Genzyme. That is not good unless it captures more market share with Vutrisiran. I think company will try to keep patients on Onpattro as much as it can.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 98
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
34689 Re: Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week Steve_382 0 9/12/2019 3:08:53 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...